News/Blogs
New Drug, Generic, and Biosimilar Pipeline Report
By constantly monitoring the pipeline, you can ensure that you are providing the most clinically effective and cost-efficient options available. Here is what you can expect from our report:
- A list of newly approved brand-name drugs
- Key generic and biosimilar entries
- Administration routes, approval timelines, and cost projections
- Applicable therapeutic areas
Download the Q3 2024 pipeline report PDF to save it and share it with your clients and colleagues.
We publish this pipeline report quarterly to assist your pharmacy benefit management planning and strategies. You can read about our clinical services and strategies or talk to a Sales Rep to learn more.
New Drug Pipeline
| GENERIC NAME | BRAND NAME (Manufacturer if drug name unavailable) | ROUTE OF ADMINISTERED | STATUS | ESTIMATED COST | THERAPEUTIC AREA | SPECIALTY OR TRADITIONAL |
|---|---|---|---|---|---|---|
| Mavorixafor | Xolremdi | Oral | Approved Apr 2024 | $100,000-$200,000 annually | Autoimmune | Specialty |
| Pivmecillinam | Pivya | Oral | Approved Apr 2024 | $200-$500 per course | Anti-Infectives: Antibiotics | Traditional |
| Tovorafenib | Ojemda | Oral | Approved Apr 2024 | $250,000 annually | Cancer: Brain | Specialty |
| Danicopan | Voydeya | Oral | Launched Apr 2024 | $50,000 annually | Hematologic: Paroxysmal nocturnal hemoglobinuria | Specialty |
| Rivoceranib | (Jiangsu Hengrui Medicine LSK BioPharma) | Oral | CRL May 2024 | TBD | Cancer: Gastrointestinal | Specialty |
| Elafibranor | Iqirvo | Oral | Approved Jun 2024 | 139,430 | Endocrine: Primary Biliary Cholangitis | Specialty |
| Sofpironium | Sofdra | Topical | Approved Jun 2024 | $5,000-$10,000 annually | Dermatology: Hyperhidrosis | Traditional |
| Crovalimab | PiaSky | Intravenous/ Subcutaneous | Approved Jun 2024 | $450,000 | Hematological: Paroxysmal Nocturnal Hemoglobinuria | Specialty |
| Ensifentrine | (Ligand Pharma) | Inhaled | Jun 2024 | $18,000 annually | Respiratory: Asthma/COPD | Traditional |
| Follitropin Delta | Rekovelle | Subcutaneous* | 1H2024 | TBD | Endocrine: Infertility | Specialty |
| Deuruxolitinib | (Concert/Sun) | Oral | Jul 2024 | TBD | Dermatology: Alopecia Areata | Specialty |
| Galantamine Benzoate | (Alpha Cognition) | Oral | Jul 2024 | TBD | Central Nervous System: Alzheimer’s/ Dementia | Traditional |
| Naloxone | Orexo | Nasal* | Jul 2024 | TBD | Addiction/Substance Abuse | Traditional |
| Palopegteriparatide | TransCon PTH | Subcutaneous | Aug 2024 | $100,000-$300,000 annually | Endocrine: Hypoparathyroidism | Specialty |
| Midomafetamine (MDMA) | (MAPS PBC; Lykos Therapeutics) | Oral | Aug 2024 | $5,000-$10,000 per course | Central Nervous System: Mood Disorders | Specialty |
| Seladelpar | (CymaBay Therapeutics) | Oral | Aug 2024 | $110,000 annually | Gastrointestinal: Primary biliary cholangitis | Specialty |
| Vorasidenib | (Servier Laboratories) | Oral | Aug 2024 | TBD | Cancer: Glioma | Specialty |
| Arimoclomol | Miplyffa | Oral | Sept 2024 | $500,000- $1,000,000 | Endocrine: Niemann-Pick disease Type C | Specialty |
| Ocrelizumab | Ocrevus | Subcutaneous | Sept 2024 | $78,000 | Central Nervous System: Multiple Sclerosis | Specialty |
| Revumenib | (Syndax) | Oral | Sept 2024 | TBD | Cancer: Leukemia | Specialty |
| Tradipitant | (Vanda Pharmaceuticals) | Oral | Sept 2024 | $10,000 per course | Gastroenterology: Nausea | Specialty |
| Xanomeline; Trospium Chloride | KarXT | Oral | Sept 2024 | $20,000-$30,000 annually | Central Nervous System: Schizophrenia | Traditional |
| Lebrikizumab | (Eli Lilly) | Subcutaneous | Oct 2024 | $50,000 | Dermatology: Atopic Dermatitis | Specialty |
| Acoramidis | (BridgeBio/Eidos Therapeutics) | Oral | Nov 2024 | $200,000-$300,000 annually | Endocrine: Metabolic | Specialty |
| Govorestat | (Applied Therapeutics) | Oral | Nov 2024 | TBD | Endocrine: Metabolic | Specialty |
| Nemolizumab | Mitchga | Subcutaneous | Dec 2024 | TBD | Dermatology | Specialty |
| Rilpivirine | Edurant | Oral | 2Q2024 | $17,700 annually | Anti-Infectives: HIV | Traditional |
| Insulin icodec | (Novo Nordisk) | Subcutaneous | 3Q2024 | $5,000 annually | Endocrine: Diabetes | Traditional |
| Glepaglutide | (Zeland Pharma) | Subcutaneous | Dec 2024 | $540,000 annually | Gastrointestinal: Short Bowel Syndrome | Specialty |
| Lazertinib | (YuHan) | Oral | 4Q2024 | TBD | Cancer: Non-Small Cell Lung Cancer | Specialty |
| Vicagrel | (Jiangsu Vcare Pharmatech) | Oral | 4Q2024 | $5,000-$10,000 annually | Cardiovascular: Acute Coronary Syndrome | Specialty |
Source: IPD Analytics, 2024
Generic and Biosimilar Pipeline
| DRUG NAME | BRAND NAME | ROUTE OF ADMINISTRATION | STATUS | ESTIMATED 2023 US SALES (MILLIONS) | THERAPEUTIC AREA | BIOSIMILAR OR TRADITIONAL |
|---|---|---|---|---|---|---|
| Risperidone | Risvan | Intramuscular | Approved Apr 2024 | $15,000- $35,000 | Central Nervous System: Antipsychotic | Traditional |
| Hercessi (Trastuzumab) | Herceptin | Intravenous | Apr 2024 | $559 | Cancer: Breast | Biosimilar |
| Xlucane (Ranibizumab) | Lucentis | Intravitreal* | CRL Apr 2024 | $1,242 | Ophthalmic: Macular Degeneration | Biosimilar |
| Edaravone | Radicava | Intravenous | Approved May 2024 | $330 | Central Nervous System: ALS | Biosimilar |
| Aflibercept | Eylea | Intravitreal | Jun 2024 | $6,795 | Ophthalmic: Macular Degeneration | Biosimilar |
| Liraglutide | Victoza | Subcutaneous | Approved Jun 2024 | $3,678 | Endocrine: Diabetes | Traditional |
| Nilotinib | Tasigna | Oral | 1H2024 | $1,242 | Cancer: Leukemia | Biosimilar |
| Dasatinib | Sprycel | Oral | Sept 2024 | $$2,528 | Cancer | Biosimilar |
| Oxcarbazepine | Oxtellar XR | Oral | Sept 2024 | $230 | Central Nervous System: Epilepsy | Traditional |
| Tocilizumab (Tyenne) | Prolia | Subcutaneous | Nov 2024 | $3,753 | Cancer | Biosimilar |
| Phentermine/ Topiramate | Qsymia | Oral | Dec 2024 | $51 | Endocrine: Obesity | Traditional |
| Raltegravir | Isentress | Oral | 2024 | $355 | Anti-Infectives: HIV | Traditional |
| Teduglutide | Gattex | Subcutaneous | 2024 | $500 | Gastrointestinal | Biosimilar |
| Tocilizumab (Tyenne) | Actemra | Intravenous* | Jan 2025 | $1,048 | Anti-Inflammatory | Biosimilar |
| Ustekinumab | Stelara | Subcutaneous | Jan 2025 | $20,616 | Anti-Inflammatory | Biosimilar |
Source: IPD Analytics, 2024
Key
| Launched MM YYYY | Month and year drug was launched | Withdrawn | Drug has been withdrawn from FDA approval | ||||
| Approved MM YYYY | Month and year drug was approved | CRL | Complete Response Letter – Incomplete FDA Application | ||||
| Date | Updated release date | ||||||
Nothing herein is or shall be construed as a promise or representation regarding past or future events, and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.
Past Quarterly Pipeline Reports
Click the links below to download past quarterly reports.
About Serve You Rx
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for over 37 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.
